MedWatch

Eli Lilly presents new data on Victoza challenger

Novo Nordisk’s U.S. rival, Eli Lilly, has presented positive data for the diabetes drug, Dulaglutide, which analysts and investors see as a serious rival to Novo Nordisk’s GLP-1 success.

Foto: Eli Lilly

Eli Lilly’s GLP-1 analogue, Dulaglutide, is better at controlling blood sugar levels than three other major diabetes products. At least that is what clinical data from three phase III trials, published by the American pharma group the past weekend at the world’s largest diabetes congress held by the American Diabetes Association, indicate.

The three diabetes drugs in question are generic drug metformin, Byetta (exenatide) from Bristol-Myers Squibb, and Merck’s blockbuster Januvia (sitagliptin). The three trials also show that diabetes patients shed twice as many kilos by using Dulaglutide instead of Januvia.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier